AU744523B2 - Methods and compositions for the protection of mitochondria - Google Patents
Methods and compositions for the protection of mitochondria Download PDFInfo
- Publication number
- AU744523B2 AU744523B2 AU63325/98A AU6332598A AU744523B2 AU 744523 B2 AU744523 B2 AU 744523B2 AU 63325/98 A AU63325/98 A AU 63325/98A AU 6332598 A AU6332598 A AU 6332598A AU 744523 B2 AU744523 B2 AU 744523B2
- Authority
- AU
- Australia
- Prior art keywords
- radiation
- damage
- ergothioneine
- mitochondria
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 210000003470 mitochondria Anatomy 0.000 title claims description 56
- 239000000203 mixture Substances 0.000 title claims description 54
- 238000000034 method Methods 0.000 title claims description 52
- SSISHJJTAXXQAX-ZETCQYMHSA-N L-ergothioneine Chemical compound C[N+](C)(C)[C@H](C([O-])=O)CC1=CNC(=S)N1 SSISHJJTAXXQAX-ZETCQYMHSA-N 0.000 claims description 97
- 230000006378 damage Effects 0.000 claims description 41
- 230000005855 radiation Effects 0.000 claims description 35
- 239000003642 reactive oxygen metabolite Substances 0.000 claims description 33
- 239000002502 liposome Substances 0.000 claims description 32
- 241000124008 Mammalia Species 0.000 claims description 24
- 230000004792 oxidative damage Effects 0.000 claims description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 17
- 201000010099 disease Diseases 0.000 claims description 15
- 230000001413 cellular effect Effects 0.000 claims description 13
- 230000006676 mitochondrial damage Effects 0.000 claims description 12
- 238000011282 treatment Methods 0.000 claims description 11
- 239000002246 antineoplastic agent Substances 0.000 claims description 10
- 230000000254 damaging effect Effects 0.000 claims description 10
- 239000003937 drug carrier Substances 0.000 claims description 10
- 230000001225 therapeutic effect Effects 0.000 claims description 10
- 239000001301 oxygen Substances 0.000 claims description 9
- 229910052760 oxygen Inorganic materials 0.000 claims description 9
- 238000002485 combustion reaction Methods 0.000 claims description 7
- 208000002177 Cataract Diseases 0.000 claims description 6
- 241000208125 Nicotiana Species 0.000 claims description 6
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 6
- 230000002685 pulmonary effect Effects 0.000 claims description 6
- 230000000699 topical effect Effects 0.000 claims description 6
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 5
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 5
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 5
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims description 5
- 239000005642 Oleic acid Substances 0.000 claims description 5
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 5
- WLNARFZDISHUGS-MIXBDBMTSA-N cholesteryl hemisuccinate Chemical compound C1C=C2C[C@@H](OC(=O)CCC(O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 WLNARFZDISHUGS-MIXBDBMTSA-N 0.000 claims description 5
- 206010012601 diabetes mellitus Diseases 0.000 claims description 5
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 5
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 5
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 5
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims description 5
- 201000001320 Atherosclerosis Diseases 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims description 4
- 206010057430 Retinal injury Diseases 0.000 claims description 4
- 230000001093 anti-cancer Effects 0.000 claims description 4
- 230000003412 degenerative effect Effects 0.000 claims description 4
- 230000005670 electromagnetic radiation Effects 0.000 claims description 4
- 239000003344 environmental pollutant Substances 0.000 claims description 4
- 208000002780 macular degeneration Diseases 0.000 claims description 4
- 231100000719 pollutant Toxicity 0.000 claims description 4
- 238000001959 radiotherapy Methods 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 206010014561 Emphysema Diseases 0.000 claims description 3
- 208000018565 Hemochromatosis Diseases 0.000 claims description 3
- 206010033645 Pancreatitis Diseases 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 208000019155 Radiation injury Diseases 0.000 claims description 3
- 208000031306 Rare hereditary hemochromatosis Diseases 0.000 claims description 3
- 208000014604 Specific Language disease Diseases 0.000 claims description 3
- 208000002903 Thalassemia Diseases 0.000 claims description 3
- 201000007201 aphasia Diseases 0.000 claims description 3
- 230000001363 autoimmune Effects 0.000 claims description 3
- 229910001385 heavy metal Inorganic materials 0.000 claims description 3
- 239000000017 hydrogel Substances 0.000 claims description 3
- 231100000268 induced nephrotoxicity Toxicity 0.000 claims description 3
- 238000007917 intracranial administration Methods 0.000 claims description 3
- 238000007913 intrathecal administration Methods 0.000 claims description 3
- 238000007914 intraventricular administration Methods 0.000 claims description 3
- 239000006210 lotion Substances 0.000 claims description 3
- 210000004962 mammalian cell Anatomy 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- 201000006938 muscular dystrophy Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 claims description 2
- -1 fallout Substances 0.000 claims description 2
- 239000003527 fibrinolytic agent Substances 0.000 claims description 2
- 230000003480 fibrinolytic effect Effects 0.000 claims description 2
- 239000003317 industrial substance Substances 0.000 claims description 2
- 230000005764 inhibitory process Effects 0.000 claims description 2
- 238000001361 intraarterial administration Methods 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 238000007912 intraperitoneal administration Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 230000036542 oxidative stress Effects 0.000 claims description 2
- 238000007911 parenteral administration Methods 0.000 claims description 2
- 239000003208 petroleum Substances 0.000 claims description 2
- 231100000572 poisoning Toxicity 0.000 claims description 2
- 230000000607 poisoning effect Effects 0.000 claims description 2
- 230000002285 radioactive effect Effects 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 239000003053 toxin Substances 0.000 claims description 2
- 231100000765 toxin Toxicity 0.000 claims description 2
- 108700012359 toxins Proteins 0.000 claims description 2
- 239000008177 pharmaceutical agent Substances 0.000 claims 3
- 208000033116 Asbestos intoxication Diseases 0.000 claims 1
- 208000005374 Poisoning Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 206010042496 Sunburn Diseases 0.000 claims 1
- 206010003441 asbestosis Diseases 0.000 claims 1
- 229940093497 ergothioneine Drugs 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- 239000002699 waste material Substances 0.000 claims 1
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 23
- 210000004027 cell Anatomy 0.000 description 20
- 210000001519 tissue Anatomy 0.000 description 16
- 230000000694 effects Effects 0.000 description 14
- 238000009472 formulation Methods 0.000 description 14
- 239000003814 drug Substances 0.000 description 10
- 239000008194 pharmaceutical composition Substances 0.000 description 10
- 210000002510 keratinocyte Anatomy 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 210000004072 lung Anatomy 0.000 description 8
- 230000002438 mitochondrial effect Effects 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical group N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 7
- 210000003491 skin Anatomy 0.000 description 7
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 6
- 238000000134 MTT assay Methods 0.000 description 6
- 231100000002 MTT assay Toxicity 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 210000001700 mitochondrial membrane Anatomy 0.000 description 5
- 230000001590 oxidative effect Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000008499 blood brain barrier function Effects 0.000 description 4
- 210000001218 blood-brain barrier Anatomy 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 3
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 206010061216 Infarction Diseases 0.000 description 3
- 238000012387 aerosolization Methods 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 229940034982 antineoplastic agent Drugs 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 238000005538 encapsulation Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000007574 infarction Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 239000007800 oxidant agent Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 108010006654 Bleomycin Proteins 0.000 description 2
- 206010048610 Cardiotoxicity Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 206010029164 Nephrotic syndrome Diseases 0.000 description 2
- 208000012641 Pigmentation disease Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 229940009456 adriamycin Drugs 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 238000011319 anticancer therapy Methods 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000010425 asbestos Substances 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229960001561 bleomycin Drugs 0.000 description 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 2
- 231100000259 cardiotoxicity Toxicity 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000037149 energy metabolism Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 210000003463 organelle Anatomy 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 231100000760 phototoxic Toxicity 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000010410 reperfusion Effects 0.000 description 2
- 229910052895 riebeckite Inorganic materials 0.000 description 2
- 230000037380 skin damage Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000011285 therapeutic regimen Methods 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 206010073303 Exposure via inhalation Diseases 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 241000097929 Porphyria Species 0.000 description 1
- 208000010642 Porphyrias Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000000809 air pollutant Substances 0.000 description 1
- 231100001243 air pollutant Toxicity 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 231100000223 dermal penetration Toxicity 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 231100000317 environmental toxin Toxicity 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000003700 hair damage Effects 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000002663 nebulization Methods 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 230000009092 tissue dysfunction Effects 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Lubricants (AREA)
- Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3874997P | 1997-02-20 | 1997-02-20 | |
| US60/038749 | 1997-02-20 | ||
| US09/026198 | 1998-02-19 | ||
| US09/026,198 US6103746A (en) | 1997-02-20 | 1998-02-19 | Methods and compositions for the protection of mitochondria |
| PCT/US1998/003352 WO1998036748A1 (en) | 1997-02-20 | 1998-02-20 | Methods and compositions for the protection of mitochondria |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU6332598A AU6332598A (en) | 1998-09-09 |
| AU744523B2 true AU744523B2 (en) | 2002-02-28 |
Family
ID=26700898
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU63325/98A Ceased AU744523B2 (en) | 1997-02-20 | 1998-02-20 | Methods and compositions for the protection of mitochondria |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US6103746A (https=) |
| EP (1) | EP0981345A1 (https=) |
| JP (1) | JP2001513760A (https=) |
| AU (1) | AU744523B2 (https=) |
| WO (1) | WO1998036748A1 (https=) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6479533B1 (en) | 1997-02-20 | 2002-11-12 | Applied Genetics Incorporated Dermatics | Methods and compositions for the protection of mitochondria |
| CA2319131A1 (en) | 1998-01-26 | 1999-07-29 | Walter H. Moos | Mitochondria protecting agents for treating mitochondria associated diseases |
| JP2001064158A (ja) * | 1999-06-25 | 2001-03-13 | Terumo Corp | リポソーム |
| FR2809000B1 (fr) * | 2000-05-18 | 2002-08-09 | Oreal | Utilisation d'ergothioneine et/ou de ses derives comme agent anti-pollution |
| WO2001090332A2 (en) | 2000-05-23 | 2001-11-29 | The University Of Texas System | Dna repair polypeptides and methods of use |
| US6733797B1 (en) | 2000-11-15 | 2004-05-11 | William K. Summers | Neuroceutical for improving memory and cognitive abilities |
| AU2003230770A1 (en) * | 2002-03-28 | 2003-10-13 | Oxis International, Inc. | Neuroprotectant methods, compositions, and screening methods thereof |
| KR20060015265A (ko) * | 2003-05-30 | 2006-02-16 | 알자 코포레이션 | 제제의 폐 투여 방법 |
| US20050042233A1 (en) * | 2003-08-21 | 2005-02-24 | Christopher Marrs | Stabilized compositions containing an oxygen-labile active agent and a fungal extract |
| US20050042306A1 (en) * | 2003-08-21 | 2005-02-24 | Christopher Marrs | Stabilized compositions containing an oxygen-labile active agent |
| FR2865398B1 (fr) * | 2004-01-23 | 2009-07-03 | Jean Noel Thorel | Compositions destinees a la protection cellulaire vis-a-vis des uva, de la peau, et/ou des phaneres. |
| US8492106B2 (en) | 2004-05-24 | 2013-07-23 | Universitat Zu Koln | Identification methods for ergothioneine transporter modulators and therapeutic uses thereof |
| US20070282318A1 (en) * | 2006-05-16 | 2007-12-06 | Spooner Gregory J | Subcutaneous thermolipolysis using radiofrequency energy |
| EP2134198A4 (en) * | 2007-03-07 | 2012-08-29 | Robert B Beelman | USE OF ERGOTHIONEIN AS A PRESERVATIVE AGENT IN FOOD AND BEVERAGE |
| FR2915397B1 (fr) | 2007-04-27 | 2012-01-20 | Vincience | Composition pharmaceutique et/ou cosmetique contenant des principes actifs activateurs de l'aconitase |
| FR2918893B1 (fr) | 2007-07-20 | 2012-10-19 | Vincience | Utilisation d'un principe actif issu du lin pour preparer une composition destinee a activer le cytochrome c |
| US8257753B2 (en) | 2007-07-20 | 2012-09-04 | Isp Investments Inc. | Use of an active principle originating from flax in a composition intended to reinforce the barrier function of the skin and to protect the skin and the appendages against external aggressions |
| US8563500B2 (en) * | 2007-09-05 | 2013-10-22 | Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts | Methods and compounds for treating diseases caused by reactive oxygen species |
| US7767826B2 (en) * | 2007-10-05 | 2010-08-03 | Pharmatech International, Inc. | Process for the synthesis of L-(+)-ergothioneine |
| FR2924334B1 (fr) * | 2007-11-30 | 2016-03-25 | Lvmh Rech | Composition cosmetique comprenant l'acide 2-glucoside ascorbique et l'ergothioneine. |
| EP3268354B1 (en) | 2015-03-13 | 2020-05-06 | Mironova Innovations, LLC | Nalpha, nalpha, nalpha-trialkyl histidine derivatives useful for the preparation of ergothioneine compounds |
| WO2019089878A1 (en) | 2017-11-02 | 2019-05-09 | Colorado Seminary, Owner and Operator of University of Denver | Methods of treating microbial infection and inflammation |
| WO2019173159A1 (en) | 2018-03-05 | 2019-09-12 | Mironova Innovations, Llc | Ergothioneine compositions and methods for maintaining and/or increasing vitamin c levels in cells and organisms |
| PH12021551300A1 (en) * | 2018-12-05 | 2022-03-28 | Celagenex Res India Pvt Ltd | Synergistic compositions of bioactive agents for optimizing cellular health |
| EP3925636A1 (en) * | 2020-06-17 | 2021-12-22 | Centre Of Experimental Medicine Slovak Academy Of Sciences Institute Of Experimental Pharmacology | Composite membranes containing a smart-released cytoprotectant targeting the inflamed tissue and use thereof |
| CN112641777B (zh) * | 2021-01-07 | 2023-02-03 | 山东华熙海御生物医药有限公司 | 麦角硫因类物质在制备防治缺血性脑卒中药物中的应用 |
| JP7817249B2 (ja) | 2021-04-26 | 2026-02-18 | サントリーホールディングス株式会社 | 免疫細胞の代謝促進用組成物 |
| CN117396198A (zh) * | 2021-05-20 | 2024-01-12 | 南京纽邦生物科技有限公司 | 改善和预防年龄相关性肌肉退化的方法 |
| CN117580573A (zh) * | 2021-06-22 | 2024-02-20 | 南京纽邦生物科技有限公司 | L-麦角硫因用于缓解和预防年龄相关的视力退化 |
| CN116390716A (zh) * | 2021-06-22 | 2023-07-04 | 南京纽邦生物科技有限公司 | L-麦角硫因用于改善和预防年龄相关的玻璃体变性 |
| AU2021457422A1 (en) * | 2021-07-28 | 2024-02-15 | Nanjing Nutrabuilding Bio-Tech Co., Ltd. | L-ergothioneine and therapeutic uses thereof |
| CN118576592A (zh) * | 2023-03-02 | 2024-09-03 | 中国科学院高能物理研究所 | 麦角硫因或其组合物在制备辐射防护剂中的应用 |
| CN118121502B (zh) * | 2024-01-25 | 2024-09-24 | 合肥和晨生物科技有限公司 | 麦角硫因组合物包埋递送制剂及其制备方法和应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994004129A2 (de) * | 1992-08-26 | 1994-03-03 | Beiersdorf Ag | Kosmetische und dermatologische lichtschutzformulierungen mit einem gehalt an thiolen und/oder thiolderivaten |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60202806A (ja) * | 1984-03-26 | 1985-10-14 | Sansho Seiyaku Kk | 色白化粧料 |
| JPS638335A (ja) * | 1986-06-27 | 1988-01-14 | Sansho Seiyaku Kk | メラニン生成抑制外用薬剤 |
| US4898878A (en) * | 1987-10-02 | 1990-02-06 | The Board Of Regents Of The University Of Washington | Antioxidant thiohistidine compounds |
| US5190762A (en) * | 1988-07-06 | 1993-03-02 | Applied Genetics, Inc. | Method of administering proteins to living skin cells |
| US5272166A (en) * | 1990-04-09 | 1993-12-21 | The Rockefeller University | Method for selective reduction of Lp(a) |
| FR2707087B1 (fr) * | 1993-06-28 | 1995-10-13 | Bioxytech | Nouveau procédé de préparation de l'ergothionéine. |
-
1998
- 1998-02-19 US US09/026,198 patent/US6103746A/en not_active Expired - Lifetime
- 1998-02-20 EP EP98907551A patent/EP0981345A1/en not_active Ceased
- 1998-02-20 JP JP53690998A patent/JP2001513760A/ja not_active Ceased
- 1998-02-20 WO PCT/US1998/003352 patent/WO1998036748A1/en not_active Ceased
- 1998-02-20 AU AU63325/98A patent/AU744523B2/en not_active Ceased
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994004129A2 (de) * | 1992-08-26 | 1994-03-03 | Beiersdorf Ag | Kosmetische und dermatologische lichtschutzformulierungen mit einem gehalt an thiolen und/oder thiolderivaten |
Also Published As
| Publication number | Publication date |
|---|---|
| EP0981345A1 (en) | 2000-03-01 |
| JP2001513760A (ja) | 2001-09-04 |
| US6103746A (en) | 2000-08-15 |
| AU6332598A (en) | 1998-09-09 |
| WO1998036748A1 (en) | 1998-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU744523B2 (en) | Methods and compositions for the protection of mitochondria | |
| US8461136B2 (en) | Compositions and methods for protecting cells during cancer chemotherapy and radiotherapy | |
| US6479533B1 (en) | Methods and compositions for the protection of mitochondria | |
| EP3283056B1 (en) | Nanostructures comprising cobalt porphyrin-phospholipid conjugates and polyhistidine-tags | |
| US8029770B2 (en) | Caffeine salt complexes and methods for using the same in the prevention or treatment of cancer | |
| US20030118539A1 (en) | Polyamines and analogs for protecting cells during cancer chemotherapy and radiotherapy | |
| Celia et al. | Liposomal delivery improves the growth-inhibitory and apoptotic activity of low doses of gemcitabine in multiple myeloma cancer cells | |
| US20150224202A1 (en) | Formulations and uses for microparticle delivery of zinc protoporphyrins | |
| JP2019006697A (ja) | 活性酸素消去剤 | |
| Carbone et al. | Nanoencapsulation strategies for the delivery of novel bifunctional antioxidant/σ1 selective ligands | |
| CA2281799A1 (en) | Methods and compositions for the protection of mitochondria | |
| US20130005824A1 (en) | Treatment of ischemic tissue | |
| WO2023009901A2 (en) | Composition comprising photosensitzer compound and activation thereof | |
| US10918599B2 (en) | Serum-stable compositions and methods for light-triggered release of materials | |
| US20040156799A1 (en) | Cancer treatment method and compositions | |
| KR100514009B1 (ko) | 1,2,4-벤조트리아진옥사이드제제 | |
| MXPA99007701A (en) | Methods and compositions for the protection of mitochondria | |
| WO2002098399A2 (en) | Cancer treatment method and compositions comprising compounds of the ginger family | |
| US20050215524A1 (en) | Methods and compositions for improving photodynamic therapy through administration of lipids | |
| CN112672735A (zh) | 对由辐射暴露引起的损伤的治疗和预防 | |
| WO2001070220A1 (en) | A method of administering liposomal encapsulated taxane | |
| WO2023022623A1 (ru) | Средство для профилактики и лечения инфекционно-воспалительных заболеваний | |
| RESHETOV | Ecole Doctorale BioSE (Biologie-Santé-Environnement) | |
| Octavio | Inhibition of skin inflammation by baicalin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |